首页|胃癌免疫治疗的临床研究进展

胃癌免疫治疗的临床研究进展

扫码查看
晚期胃癌治疗选择有限,易发生化疗耐药.目前,包括免疫检查点抑制剂、过继细胞疗法、肿瘤疫苗、非特异免疫增强剂及细胞因子疗法在内的免疫疗法对胃癌显示出了良好的疗效.载体药物及3D打印技术也在临床前实验中取得了疗效.临床试验采用免疫肿瘤学单一疗法或联合免疫化学疗法来提高胃癌病人的总体生存时间和客观反应率.根据初步证据,我们相信免疫治疗可以积极影响自然病史,改善胃癌病人的预后.
Research and clinical progress of immunotherapy for gastric cancer
Due to the limited treatment options of advanced gastric cancer and prone to chemoresistance,there is an urgent need for novel treatment methods to improve the prognosis of these patients.At present,immunotherapy including immune checkpoint inhibitor,adoptive cell therapy,tumor vaccine,nonspecific immune enhancer and cytokine therapy has shown good curative effect on gastric cancer.Additionally,carrier drugs and 3D printing technology have also achieved curative effects in preclinical experiments.Clinical trials used immunooncology monotherapy or combined immunochemotherapy to improve the overall survival time and objective response rate of patients with gastric cancer.Based on the preliminary evidence,we believe that immunotherapy can positively affect the natural history and improve the prognosis of patients with gastric cancer.

gastric cancerimmunotherapyimmune checkpoint inhibitorsadoptive cell therapytumor vaccine

黄涛、汪安新、付广

展开 >

430081 武汉,武汉科技大学附属普仁医院胃肠外科

胃癌 免疫治疗 免疫检查点抑制剂 过继细胞疗法 肿瘤疫苗

2024

临床外科杂志
中华医学会湖北分会

临床外科杂志

CSTPCD
影响因子:0.716
ISSN:1005-6483
年,卷(期):2024.32(1)
  • 25